InvestorsHub Logo
Followers 696
Posts 31831
Boards Moderated 8
Alias Born 03/16/2014

Re: $Pistol Pete$ post# 182120

Wednesday, 03/21/2018 4:39:48 PM

Wednesday, March 21, 2018 4:39:48 PM

Post# of 245468
$$ACBFF Aurora will now accelerate a number of strategic initiatives, the key objectives of which are to:

1.
Rapidly Increase Production Capacity, including derivatives.

a.
Increase current production capacity by leveraging Aurora`s best practices.

b.
Leverage the capabilities of ALPS (Aurora Larssen Projects Ltd) to accelerate construction and commissioning of CanniMed`s expansion that, at full capacity, should result in an estimated 17,000 kg to 21,000 kg per annum of total production capacity.

c.
Accelerate construction of the previously announced (by CanniMed) cannabis oils processing facility, with a design capacity of up to 720,000 liters of annual oil production. Leveraging this capacity and the extraction capabilities of RTI will position Aurora as leader in cannabis and hemp extraction capacity.

2.
Complete EU GMP certification of CanniMed's existing facility. Aurora will apply its experience through ALPS and Pedanios to fast track EU GMP certification, which would enable Aurora to significantly increase shipments of cannabis for the international medical markets.

3.
Leverage CanniMed's and Aurora's international distribution networks to develop existing and penetrate new international markets. To date, the companies are active in Canada, Germany, Denmark, Italy, Cayman Islands, Australia and South Africa, and actively pursuing market entry into additional countries.

4.

Accelerate CanniMed's patient registration through CanvasRx.

5.

Conversely, leverage CanniMed's relationship with over 5,000 physicians to broaden market reach for Aurora's medical products. Unlike most other licensed producers, CanniMed has not used patient aggregators, but, over the years, built a network of physicians prescribing CanniMed oils through outreach and education. This organic growth has proven very cost effective and has built a very solid base from which to drive further growth.

6.

Market and develop new, high-margin, standardized dosage forms, including capsules, sub-lingual wafers and topical applications (CanniMed recently successfully launched a topical cream).

7.
Engage in clinical and scientific research to develop new, high value-add product lines and increase the recognition of the combined entity among the international medical community.

8.

Leverage the combined entity's expanded genetics portfolio to provide complimentary products to both companies' patient bases.

9.

Evaluate opportunities to leverage CanniMed`s Saskatchewan presence for penetration of the adult consumer use market in the province.

https://investor.auroramj.com/press-releases/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.